# Niels W.C.J. van de Donk

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/niels-w-c-j-van-de-donk/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,885 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 80 |
| i10-index | 261 |
| Last Known Institution | National Cancer Center |
| OpenAlex ID | https://openalex.org/A5032546995 |
| ORCID iD | https://orcid.org/0000-0002-7445-2603 |
| Works | 620 |

## Researcher papers

- [Teclistamab in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/teclistamab-in-relapsed-or-refractory-multiple-myeloma/)
- [Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study](https://scholariq.org/papers/bortezomib-thalidomide-and-dexamethasone-with-or-without-daratumumab-before-and/)
- [Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma](https://scholariq.org/papers/talquetamab-a-t-cell-redirecting-gprc5d-bispecific-antibody-for-multiple-myeloma/)
- [Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma](https://scholariq.org/papers/daratumumab-bortezomib-lenalidomide-and-dexamethasone-for-multiple-myeloma/)
- [Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study](https://scholariq.org/papers/teclistamab-a-b-cell-maturation-antigen-cd3-bispecific-antibody-in-patients-with/)
- [LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma](https://scholariq.org/papers/locommotion-a-prospective-non-interventional-multinational-study-of-real-life/)
- [Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial](https://scholariq.org/papers/maintenance-with-daratumumab-or-observation-following-treatment-with-bortezomib/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

## Researcher university

- [National Cancer Center](https://scholariq.org/institutions/national-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.